IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Markel Group Inc.

Markel Group Inc. grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,626 shares of the medical research company's stock after purchasing an additional 6,800 shares during the quarter. Markel Group Inc.'s holdings in IQVIA were worth $11,714,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IQV. Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of IQVIA by 9.9% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,610 shares of the medical research company's stock valued at $1,067,000 after acquiring an additional 415 shares during the period. GAMMA Investing LLC acquired a new position in shares of IQVIA in the 4th quarter valued at $60,000. Marks Group Wealth Management Inc increased its holdings in shares of IQVIA by 0.8% in the 4th quarter. Marks Group Wealth Management Inc now owns 30,807 shares of the medical research company's stock valued at $7,128,000 after acquiring an additional 259 shares during the period. Aspire Private Capital LLC increased its holdings in shares of IQVIA by 8.6% in the 4th quarter. Aspire Private Capital LLC now owns 2,957 shares of the medical research company's stock valued at $684,000 after acquiring an additional 235 shares during the period. Finally, CWM LLC grew its position in IQVIA by 5.5% in the 4th quarter. CWM LLC now owns 3,980 shares of the medical research company's stock valued at $921,000 after buying an additional 207 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares of the company's stock, valued at $5,031,894. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Kevin C. Knightly sold 8,607 shares of the firm's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the firm's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares in the company, valued at $5,031,894. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock valued at $10,331,003 over the last 90 days. 1.60% of the stock is owned by corporate insiders.

IQVIA Trading Up 0.4 %

NYSE IQV traded up $0.90 during mid-day trading on Friday, hitting $234.88. The company's stock had a trading volume of 635,995 shares, compared to its average volume of 970,046. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The stock's fifty day simple moving average is $245.28 and its two-hundred day simple moving average is $223.02. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The firm has a market capitalization of $42.63 billion, a P/E ratio of 32.22, a price-to-earnings-growth ratio of 2.33 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. During the same quarter last year, the firm posted $2.54 earnings per share. IQVIA's revenue for the quarter was up 3.5% compared to the same quarter last year. Research analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Truist Financial lifted their price objective on shares of IQVIA from $286.00 to $297.00 and gave the company a "buy" rating in a research report on Tuesday, February 27th. UBS Group lifted their price objective on shares of IQVIA from $240.00 to $300.00 and gave the company a "buy" rating in a research report on Thursday, February 15th. Barclays lifted their price objective on shares of IQVIA from $260.00 to $265.00 and gave the company an "overweight" rating in a research report on Thursday, February 15th. Leerink Partnrs reiterated an "outperform" rating on shares of IQVIA in a research report on Monday, February 26th. Finally, SVB Leerink began coverage on shares of IQVIA in a research report on Monday, February 26th. They set an "outperform" rating and a $290.00 target price on the stock. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $256.80.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.